Table 1 (abstract P101). Patient classification in migraine categories during the HFEM study
Table 1A. Overall shift in migraine categorya | Placebo n = 104 | Fremanezumab 225 mg n = 95 | Fremanezumab 675 mg n = 96 |
 Worsen | 7 (7%) | 2 (2%) | 3 (3%) |
 Stable | 42 (40%) | 14 (15%) | 17 (18%) |
 Improve | 51 (49%) | 69 (73%) | 68 (71%) |
 Discontinued | 4 (4%) | 10 (11%) | 8 (8%) |
Table 1B: Migraine Categories Num (%) patients in 3rd month | Placebo (n = 98)b | Fremanezumab 225 mg (n = 88) | Fremanezumab 675 mg (n = 91) |
 CM | 7 (7%) | 2 (2%) | 2 (2%) |
 HFEM | 41 (42%) | 14 (16%) | 17 (19%) |
 MFEM | 28 (29%) | 22 (25%) | 21 (23%) |
 LFEM | 20 (20%) | 40 (45%) | 47 (52%) |